Population Pharmacokinetics in Oncology and Its Clinical Applications
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".
Deadline for manuscript submissions: closed (20 January 2023) | Viewed by 18724
Special Issue Editors
2. Pharmacy of the Eastern Vaud Hospitals, 1847 Rennaz, Switzerland
Interests: therapeutic drug monitoring; clinical pharmacokinetics; targeted anticancer drugs
2. Center of Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
Interests: clinical pharmacokinetics; modeling and simulation; population pharmacokinetics; model-based therapeutic drug monitoring
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to a Special issue of the peer-reviewed, open-access journal Pharmaceutics, which will be devoted to “Population Pharmacokinetics in Oncology and Its Clinical Applications”. Most traditional cytotoxic drugs are characterized by steep dose–response relationships and narrow therapeutic windows. Inter-individual pharmacokinetic (PK) variability is often substantial, making standard dosages produce very different circulating concentration profiles between patients. In recent decades, rationally designed small-molecule targeted anticancer drugs—namely, protein kinase inhibitors—were also developed. They are currently the mainstay of systemic treatment for a number of hematological malignancies and metastatic solid tumors. Because of their oral administration, they offer a greater autonomy and simpler outpatient care than cytotoxic chemotherapies and immunotherapies, thus improving the patient quality of life. However, the therapeutic response to oral targeted drugs varies widely between patients, with insufficient efficacy in certain cases and unacceptable toxicities in others. Here again, one of the main causes of this heterogeneity is their PK variability, besides fluctuating medication adherence and constitutive or acquired drug resistance of cancer cells (i.e., pharmacodynamic (PD) variability). PK variability appears also to affect to a clinically significant degree certain monoclonal antibodies which have recently entered the anticancer armamentarium, such as checkpoint inhibitors. It is increasingly recognized that definite improvements in the usage of anticancer drugs could be achieved by a better understanding of their PK–PD characteristics and by the individualization of their dosage regimen, based on both the thorough adaptation to influential patient characteristics and the measurement of plasma circulating drug concentrations (therapeutic drug monitoring, TDM).
This Special Issue aims to encourage scientists and clinicians to publish their observations, experimental results, and theoretical assumptions to capture the current state-of-the-art advances in the PK–PD characterization of anticancer agents, encompassing traditional chemotherapies, recent protein kinase inhibitors, and monoclonal antibodies. Our goal is to encourage translational efforts in bringing this knowledge closer to medical applications, such as therapeutic drug monitoring and further treatment individualization approaches. We believe that these efforts represent an important component of the widely advocated precision oncology, alongside the approaches capitalizing on tumor genetics.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: population pharmacokinetic modeling of traditional cytotoxic, small-molecule targeted anticancer drugs, monoclonal antibodies and immunotherapies; pharmacodynamic–pharmacokinetic relationship analyses of anticancer treatments (correlation between concentration, efficacy, and toxicity); and therapeutic drug monitoring development in the field of oncology.
We look forward to receiving your contributions.
Dr. Nicolas Widmer
Dr. Monia Guidi
Prof. Dr. Thierry Buclin
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- clinical pharmacokinetics
- population pharmacokinetics
- pharmacometrics
- therapeutic drug monitoring
- modeling and simulation
- precision medicine
- oncology
- targeted anticancer drugs
- protein kinase inhibitors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.